cetuximab + ridaforolimus

Cetuximab + ridaforolimus is an investigational combination therapy consisting of two agents with distinct mechanisms of action, evaluated primarily in advanced solid tumors such as head and neck cancer, non-small cell lung cancer, and colorectal cancer. Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting downstream signaling pathways involved in tumor cell proliferation and survival. Ridaforolimus is an oral small molecule inhibitor of mammalian target of rapamycin (mTOR), a key regulator of cell growth, proliferation, and angiogenesis. Preclinical studies suggest potential synergistic antitumor effects when combining mTOR inhibition with EGFR blockade. The combination has been studied in early-phase clinical trials to assess safety, tolerability, pharmacokinetics, and preliminary efficacy[1][2][4].